Beat revenue 1.3b v 1.22b(e)
ebitda weak 83.2m v 88m(e) - adjusting for outstanding claims ebitda came in at 87.4m
eps weak 12.6c v 15c(e)
guidance given in january underlying 170M ebitda is unchanged.
its not in an upgrade cycle anymore but better looking to buy soon than at end of upgrade cycle which was in mid 2019 as represents better value... need some luck with claims inflation and good management controlling costs as it doesn't seem sales is going to slow down anytime soon.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)